Mast cell inflammatory mediator signaling

Mast cell inflammatory mediator signaling refers to the complex intracellular signaling cascades that lead to the activation of mast cells and the subsequent release of potent inflammatory mediators (StatPearls, 2023). This process is primarily initiated by the cross-linking of the high-affinity IgE receptor (FcεRI) by allergen-bound IgE, but can also be triggered by other receptors such as KIT, MRGPRX2, and Toll-like receptors (PubMed, 2021). Upon activation, mast cells undergo degranulation, releasing preformed mediators like histamine and tryptase, and initiate the de novo synthesis of lipid mediators (leukotrienes, prostaglandins) and cytokines (Nature Reviews Immunology, 2015). This signaling pathway is a central driver of allergic reactions, asthma, and anaphylaxis, making it a critical focus for therapeutic intervention (Journal of Allergy and Clinical Immunology, 2020). Drugs targeting this pathway include mast cell stabilizers (e.g., Cromolyn), anti-IgE antibodies (e.g., Omalizumab), and various kinase inhibitors (e.g., targeting Syk or BTK) designed to dampen the inflammatory response (Frontiers in Immunology, 2022).

Other names

Mast cell activation pathwayMast cell degranulation signalingFcεRI-mediated signalingMast cell mediator release

Inhibition of IgE-mediated FcεRI cross-linking, stabilization of mast cell membranes to prevent degranulation, and pharmacological blockade of intracellular signaling molecules including Spleen Tyrosine Kinase (Syk), Bruton's Tyrosine Kinase (BTK), and the KIT receptor tyrosine kinase.